Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-717 + HRS-4642 + SHR-1316
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
HRS-717 + HRS-4642 + SHR-1316 (also referred to as HRS-7172 + HRS-4642 + SHR-1316) is an investigational combination regimen developed by Jiangsu Hengrui Pharmaceuticals for the treatment of advanced solid tumors, particularly advanced pancreatic cancer harboring RAS mutations or amplifications. The combination consists of three active components: HRS-7172, an orally active pan-RAS inhibitor; HRS-4642, an intravenously administered liposomal formulation of a selective KRAS G12D inhibitor; and SHR-1316 (adebrelimab), a humanized IgG4 monoclonal antibody targeting the immune checkpoint PD-L1. By simultaneously inhibiting oncogenic RAS/KRAS signaling and blocking the PD-1/PD-L1 immune checkpoint pathway, this combination is designed to overcome the immunosuppressive tumor microenvironment and enhance anti-tumor efficacy in RAS-mutated cancers.
- Other names
- HRS-717 + HRS-4642 + adebrelimabHRS-7172 + HRS-4642 + SHR-1316HRS-7172 + HRS-4642 + adebrelimabadebrelimab + HRS-4642 + HRS-717adebrelimab + HRS-4642 + HRS-7172
02
Targets
KRAS (Kirsten rat sarcoma viral oncogene homolog)NRAS (Neuroblastoma RAS viral oncogene homolog)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)HRAS (H-Ras protein)
Beyond the preview
Go deeper on HRS-717 + HRS-4642 + SHR-1316.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-717 + HRS-4642 + SHR-1316.